GlassScriptPhysician profile
Karthik Krishnamurthy
NPI 1770726291
$392,797.27
in general payments reported to CMS, 2019-2025
36 companies · $943 in 2025
The $943 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199K · 2020: $74K · 2021: $86K · 2022: $28K · 2023: $2,492 · 2024: $1,908 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,169 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,168.59 |
| Education | $174.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $117,633.98 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $105,304.47 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $65,479.30 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $60,166.05 | 2019-2022 | |
| Lilly USA, LLC | $36,043.72 | 2019-2023 | Taltz, Olumiant |
| Janssen Biotech, INC. | $1,304.59 | 2019-2025 | Tremfya |
| Kerecis Limited | $947.13 | 2021-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Amgen INC. | $552.77 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $496.97 | 2019-2023 | Aklief, Epsolay, Oracea |
| Organogenesis INC. | $490.79 | 2023-2025 | Novachor, Affinity, Puraply |
| Biofrontera INC. | $488.22 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $428.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $426.30 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $397.95 | 2019-2024 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $379.55 | 2022-2024 | Sotyktu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $366.57 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $365.91 | 2019-2020 | |
| Ucb, INC. | $322.02 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $251.95 | 2019-2025 | |
| Incyte Corporation | $161.29 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $135.26 | 2019-2024 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.84 | 2022-2024 | Spevigo |
| Stemline Therapeutics INC. | $95.07 | 2019 | |
| Arcutis Biotherapeutics, INC. | $86.77 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $58.34 | 2019-2023 | Erivedge |
| Allergan, INC. | $52.59 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $36.97 | 2020 | |
| Aclaris Therapeutics, INC. | $36.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $34.20 | 2023-2024 | Ycanth |
| Dermira, INC. | $26.94 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $24.12 | 2019 | |
| Revance Therapeutics, INC. | $19.73 | 2024 | Daxxify |
| Celgene Corporation | $16.61 | 2019 | |
| Medtronic, INC. | $14.58 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $12.87 | 2023 | Valchlor |
| Promius Pharma LLC | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karthik Krishnamurthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.